Evidence map›Paper›PMID 18789163›Full record

SynthesisBMC medical research methodology2008

The HCV Synthesis Project: scope, methodology, and preliminary results.

Rebecca K Stern, Holly Hagan, Corina Lelutiu-Weinberger, Don Des Jarlais, Roberta Scheinmann, Shiela Strauss, Enrique R Pouget, Peter Flom

Abstract readMeta-AnalysisReview
In one paragraph

Synthesis in BMC medical research methodology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca K SternCenter for Drug Use and HIV Research, National Development and Research Institutes (NDRI), 71 West 23rd Street, 8th Floor, New York, NY 10010, USA. becca_stern73@yahoo.com
Holly Hagan
Corina Lelutiu-Weinberger
Don Des Jarlais
Roberta Scheinmann
Shiela Strauss
Enrique R Pouget
Peter Flom

Funding

Synthesis: HCV Epidemiology and Prevention in Drug UsersR01DA018609 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI HAGAN, HOLLY C. · 2004 to 2006
$1.3M
NIDA NIH HHS R01 DA018609
6 · The paper itself

Abstract

backgroundThe hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine.

methodsTo summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included.

resultsWe identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia (11%) and Australia/New Zealand (10%). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27-52 reports per year after 1998.

conclusionThe data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.

Indexed as

Hepatitis CEpidemiologic MethodsFemaleHumansInformation Storage and RetrievalMalePilot ProjectsResearch DesignRisk FactorsSubstance Abuse, IntravenousSubstance-Related Disorders

Identifiers

PMID18789163
PMCPMC2546430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.